Xenon xe-133 - Generic Drug Details

What are the generic sources for xenon xe-133 and what is the scope of freedom to operate?

Xenon xe-133 is the generic ingredient in three branded drugs marketed by Curium, Ge Healthcare, Gen Electric, Lantheus Medcl, and Mallinckrodt, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for xenon xe-133. Two suppliers are listed for this compound.

Summary for xenon xe-133

US Patents:	0
Tradenames:	3
Applicants:	5
NDAs:	7
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	7
What excipients (inactive ingredients) are in xenon xe-133?	xenon xe-133 excipients list
DailyMed Link:	xenon xe-133 at DailyMed

Pharmacology for xenon xe-133

Drug Class	Inhalation Diagnostic Agent
Mechanism of Action	Radiopharmaceutical Activity

Anatomical Therapeutic Chemical (ATC) Classes for xenon xe-133

N01AX	Other general anesthetics
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

V04CX	Other diagnostic agents
V04C	OTHER DIAGNOSTIC AGENTS
V04	DIAGNOSTIC AGENTS
V	Various

US Patents and Regulatory Information for xenon xe-133

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lantheus Medcl	XENON XE 133	xenon xe-133	GAS;INHALATION	017284-001	Approved Prior to Jan 1, 1982		RX	No	No
Curium	XENON XE 133	xenon xe-133	GAS;INHALATION	018327-001	Mar 9, 1982		RX	No	No
Mallinckrodt	XENEISOL	xenon xe-133	SOLUTION;INHALATION, INJECTION	017262-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Lantheus Medcl	XENON XE 133	xenon xe-133	GAS;INHALATION	017284-002	Approved Prior to Jan 1, 1982		RX	No	No

Xenon xe-133 Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Xe-133?

Xenon-133 is a radioactive isotope primarily used in medical imaging, notably in ventilation scans to evaluate lung function. Its market relies heavily on demand from healthcare facilities and regulatory approvals.

Demand Drivers

• Medical Imaging Need: The primary driver is the growing use of lung ventilation imaging, especially in diagnosing obstructive airway diseases such as COPD and asthma.
• Regulatory Approvals: Availability and standardization of Xe-133 delivery methods influence adoption rates.
• Alternative Technologies: Use of non-radioactive imaging agents (e.g., MRI, CT) can compete with Xe-133.

Supply Factors

• Production: Xe-133 is produced as a byproduct in nuclear reactors, making supply constrained by reactor availability and regulatory concerns around radioactive waste.
• Disposal Regulations: Stringent waste management policies limit production capacity and increase operational costs.

Market Structure

• Key Players: Currently, a limited number of suppliers dominate, such as M.D. Anderson Cancer Center and commercial isotope producers like Isotech and Eckert & Ziegler.
• Market Barriers: Short half-life (~5.3 days) limits shelf life, complicating logistics and reducing market size.

Regulatory Environment

• FDA and EMA Regulations: Stringent approval pathways influence manufacturing and sales.
• Import Restrictions: Countries' nuclear regulatory frameworks shape distribution and access.

What Is the Financial Trajectory for Xe-133?

Financial prospects depend on production costs, clinical adoption, and regulatory dynamics.

Revenue Outlook

• Pricing: Xe-133 ventilation scans are priced between $300 and $600 per procedure in the US.
• Market Size: The global pulmonary imaging market was valued at approximately $2.5 billion in 2022; Xe-133's market share remains small due to limited supply and competition.

Cost Structure

• Production Costs: High, due to reactor fuel, irradiation, and waste handling.
• Distribution: Logistics entail specialized handling, adding to overall costs.

Investment and R&D Trends

• Research Funding: Limited due to the small market size; focus remains on optimizing production and delivery systems.
• Emerging Alternatives: Advances in hyperpolarized gas MRI and other imaging modalities may hinder future revenue growth.

Revenue Projections (2023–2030)

Year	Estimated Market Revenue (USD)	Key Drivers
2023	~$50 million	Stable demand; regulatory stability
2025	~$60 million	Slight growth as adoption expands
2030	~$70 million	Potential impact of alternative imaging

Note: These figures are based on current adoption rates and simulation models; actual revenue is subject to regulatory, technological, and logistical shifts.

How Do Market Trends Impact Financial Predictions?

• Growing Lung Disease Burden: Increased prevalence of COPD and asthma could stimulate demand.
• Regulatory Delays: Any delays in approval or changes in waste regulations could reduce supply, impacting revenue.
• Technological Competition: Advances in high-resolution MRI and other imaging modalities, possibly reducing the demand for Xe-133, pose risks.

What Are the Key Opportunities and Risks?

Opportunities

• Developing more efficient production methods to lower costs.
• Expanding clinical indications for Xe-133 imaging.
• Entering emerging markets with developing healthcare infrastructure.

Risks

• Supply limitations driven by nuclear regulatory hurdles.
• Competition from non-radioactive imaging agents.
• Regulatory restrictions on radioactive waste management will tighten.

Key Takeaways

• Xe-133's market remains niche, constrained by supply limitations, logistical challenges, and competition.
• Sales are expected to grow modestly, contingent on expanding clinical adoption and supply chain optimization.
• Long-term sustainability depends on regulatory stability, technological advancements, and the development of alternative imaging modalities.
• Cost structure is high; reducing production costs could significantly enhance profitability.
• Market expansion into developing countries presents growth opportunities but involves regulatory and infrastructure hurdles.

FAQs

1. Is Xe-133 a widely used lung imaging agent?
No, its use is limited to specialized nuclear medicine centers due to logistical challenges and regulatory constraints.

2. What are main competitors to Xe-133?
Hyperpolarized helium and MRI-based ventilation imaging are emerging alternatives.

3. How does nuclear regulation affect Xe-133 production?
It restricts supply by limiting reactor operations and increasing waste management costs.

4. Can technological innovations increase Xe-133's market size?
Yes, if production becomes more efficient, costs decline, and clinical indications broaden.

5. What is the outlook for Xe-133 in the next decade?
Moderate growth with potential decline if alternative imaging technologies or regulatory restrictions intensify.

References

[1] US Food and Drug Administration. 510(k) clearances for radiopharmaceuticals, 2022.
[2] MarketsandMarkets. Pulmonary Imaging Market, 2022.
[3] Eckert & Ziegler. Radioisotope Production, 2023.
[4] IAEA. Production and Supply of Medical Isotopes, 2022.